The global Fanconi anemia gene therapy program will continue to be available for patients in the USA and Europe during 2018 and 2019. In Europe, a new study, known as FANCOLEN-2, will be available at CIEMAT/Hospital del Niño Jesús in Madrid,...
Announcements